Alimena G - Search Results

1

Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Loglisci G, Salaroli A, Serrao A, Mancini M, Diverio D, Latagliata R, Alimena G. Breccia M, et al. Among authors: alimena g. Cancer Lett. 2013 Jun 1;333(1):32-5. doi: 10.1016/j.canlet.2012.12.018. Epub 2013 Jan 3. Cancer Lett. 2013. PMID: 23291359

2

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.

Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, Natalino F, Chistolini A, De Cuia R, Russo E, Morano GS, Biondo F, Spadea A, Mandelli F, Alimena G. Latagliata R, et al. Among authors: alimena g. Leuk Res. 2005 Mar;29(3):287-91. doi: 10.1016/j.leukres.2004.08.002. Leuk Res. 2005. PMID: 15661264 Clinical Trial.

3

Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.

Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, Diverio D, Mancini M, Nanni M, Mandelli F. Alimena G, et al. Cancer. 2006 Sep 1;107(5):1008-13. doi: 10.1002/cncr.22046. Cancer. 2006. PMID: 16878324 Free article.

4

Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib.

Breccia M, Cannella L, Diverio D, Streponi P, Nanni M, Stefanizzi C, Natalino F, Mecarocci S, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2008 Jan;32(1):177-80. doi: 10.1016/j.leukres.2007.05.022. Epub 2007 Aug 3. Leuk Res. 2008. PMID: 17688946

5

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.

Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F. Alimena G, et al. Leuk Res. 2008 Feb;32(2):255-61. doi: 10.1016/j.leukres.2007.06.008. Epub 2007 Aug 10. Leuk Res. 2008. PMID: 17692911 Clinical Trial.

6

Ocular side effects in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2008 Jul;32(7):1022-5. doi: 10.1016/j.leukres.2007.10.016. Epub 2007 Dec 3. Leuk Res. 2008. PMID: 18061664

7

Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.

Breccia M, Stefanizzi C, Cannella L, Latagliata R, Frustaci AM, Carmosino I, Santopietro M, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Lymphoma. 2008 Dec;49(12):2328-32. doi: 10.1080/10428190802578841. Leuk Lymphoma. 2008. PMID: 19052981

8

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.

Breccia M, Cannella L, Stefanizzi C, Santopietro M, De Cuia R, Diverio D, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2009 May;33(5):645-8. doi: 10.1016/j.leukres.2008.10.024. Epub 2008 Dec 4. Leuk Res. 2009. PMID: 19062090

9

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

Breccia M, Frustaci AM, Cannella L, Soverini S, Stefanizzi C, Federico V, Grammatico S, Santopietro M, Alimena G. Breccia M, et al. Among authors: alimena g. Cancer Chemother Pharmacol. 2009 Jun;64(1):195-7. doi: 10.1007/s00280-008-0905-5. Epub 2009 Jan 21. Cancer Chemother Pharmacol. 2009. PMID: 19156415

10

Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):21-8. doi: 10.2174/187152909787581363. Cardiovasc Hematol Disord Drug Targets. 2009. PMID: 19275574 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters